FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / Press Releases / Read Press Release


Silicon Valley Bank, aTyr Pharma Enter Into $20MM Credit Facility

November 22, 2016, 07:08 AM
Filed Under: Pharmaceuticals

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, announced it has entered into a $20 million credit facility with Silicon Valley Bank (SVB) and Solar Capital Ltd.  aTyr intends to use the additional capital to pay off existing indebtedness and for general corporate purposes to further aTyr's mission to bring meaningful therapies to patients based on its understanding of Physiocrine biology.

"We believe that managing our cost of capital and creating funding opportunities with premier partners enables us to create more value for our stockholders and deliver on our promise to patients," said John Mendlein, PhD, Chief Executive Officer of aTyr Pharma. "SVB and Solar Capital are top tier funding partners whose non-dilutive capital allows us to better manage our cash runway as we near critical inflection points for our lead candidate Resolaris™ for rare myopathies with an immune component and prepare for the clinical development of iMod.Fc for rare lung diseases."

"This funding agreement allows us to build upon our long-standing relationship with and provide additional financial support to aTyr Pharma's research and clinical development initiatives," said Anthony Flores, Director for Silicon Valley Bank. "We're happy to develop a financing partnership with the company and look forward to their development of high-value new Physiocrine-based biologics to treat a wide-variety of diseases," said Anthony Storino, Head of life science lending at Solar Capital.

aTyr Pharma will receive $10 million after execution of the loan agreement and, under the terms of the agreement, two additional $5 million tranches will be available to aTyr Pharma, subject to the achievement of certain specified milestones.

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

For more than 30 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international, and private banking services, SVB helps address the unique needs of innovators. Learn more at

Solar Capital Partners, the investment advisor to Solar Capital Ltd., Solar Senior Capital Ltd. and other affiliated funds, primarily invests in leveraged, middle market companies in the form of senior secured loans, unitranche loans, mezzanine loans, and equity securities.

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.